Review of: "Population estimates of biomarkers of exposure to carbon monoxide, nicotine, and NNK in smokers and non-smokers"

Qixin Wang[1]

1 University of Rochester

Potential competing interests: The author(s) declared that no potential competing interests exist.

This paper provide a insight of how the biomarker levels (NNAL, COHb, and NNK) can be used to identified the risk and levels of current smoker, previous smoker, and non-smoker. However, the level of NNAL and NNK in urine samples have been identified by FDA as the metabolites after tobacco smoking, other interesting metabolites can be also considered, such as the family of sphingosine, which is correlated with lung diseases related with smoking.